Eudaimonia Partners LLC boosted its position in Cytosorbents Co. (NASDAQ:CTSO – Get Rating) by 81.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,000 shares of the medical research company’s stock after purchasing an additional 9,000 shares during the period. Eudaimonia Partners LLC’s holdings in Cytosorbents were worth $31,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of CTSO. Raymond James Financial Services Advisors Inc. grew its holdings in Cytosorbents by 21.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 57,684 shares of the medical research company’s stock valued at $184,000 after buying an additional 10,141 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Cytosorbents during the first quarter worth $70,000. Renaissance Technologies LLC acquired a new stake in shares of Cytosorbents during the first quarter worth $271,000. Goldman Sachs Group Inc. boosted its holdings in shares of Cytosorbents by 129.6% during the first quarter. Goldman Sachs Group Inc. now owns 298,877 shares of the medical research company’s stock worth $954,000 after purchasing an additional 168,712 shares during the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new stake in shares of Cytosorbents during the first quarter worth $28,000. Institutional investors and hedge funds own 34.04% of the company’s stock.
Cytosorbents Price Performance
Shares of Cytosorbents stock opened at $3.37 on Monday. Cytosorbents Co. has a twelve month low of $1.03 and a twelve month high of $4.59. The stock has a market capitalization of $147.13 million, a P/E ratio of -4.49 and a beta of 0.77. The company has a current ratio of 3.47, a quick ratio of 3.12 and a debt-to-equity ratio of 0.14. The business’s fifty day moving average price is $3.26 and its 200 day moving average price is $2.17.
Wall Street Analysts Forecast Growth
About Cytosorbents
CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.
Further Reading
- Get a free copy of the StockNews.com research report on Cytosorbents (CTSO)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Want to see what other hedge funds are holding CTSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cytosorbents Co. (NASDAQ:CTSO – Get Rating).
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.
